123 related articles for article (PubMed ID: 16038281)
1. [Expression of galectin-3 in invasive prolactinomas].
Wang H; Wang MD; Ma WB; Yang D; Shi YF; Kong YG; Li SF; Li ZH; Wang RZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):380-1. PubMed ID: 16038281
[TBL] [Abstract][Full Text] [Related]
2. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-1 and transforming growth factor-β1 levels in prolactinoma and their clinical significance.
Jiang M; Mou CZ; Han T; Wang M; Yang W
J Int Med Res; 2012; 40(4):1284-94. PubMed ID: 22971480
[TBL] [Abstract][Full Text] [Related]
4. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer.
Okada K; Shimura T; Suehiro T; Mochiki E; Kuwano H
Anticancer Res; 2006; 26(2B):1369-76. PubMed ID: 16619546
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
6. The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma.
Zhang Y; He N; Zhou J; Chen Y
Clin Imaging; 2011; 35(3):165-73. PubMed ID: 21513851
[TBL] [Abstract][Full Text] [Related]
7. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
8. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
9. Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas.
Chauvet N; Romanò N; Meunier AC; Galibert E; Fontanaud P; Mathieu MN; Osterstock G; Osterstock P; Baccino E; Rigau V; Loiseau H; Bouillot-Eimer S; Barlier A; Mollard P; Coutry N
J Neuroendocrinol; 2016 Feb; 28(2):12352. PubMed ID: 26686489
[TBL] [Abstract][Full Text] [Related]
10. [Association of galectin-3 expression with biological behaviors of human colorectal carcinoma].
Zhang N; Ding YQ; Liang L
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Dec; 26(12):1685-9. PubMed ID: 17259097
[TBL] [Abstract][Full Text] [Related]
11. Prolactin levels and gender are associated with tumour behaviour in prolactinomas but Ki-67 index is not.
Cander S; Gül ÖÖ; Ertürk E; Tuncel E; Ersoy C
Endokrynol Pol; 2014; 65(3):210-6. PubMed ID: 24971922
[TBL] [Abstract][Full Text] [Related]
12. [Differential expression analysis of prolactinoma-related microRNAs].
Chen YX; Li Q; Wang CD; Su ZP; Li WQ; Chen XB; Wu ZB
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(5):320-3. PubMed ID: 22490835
[TBL] [Abstract][Full Text] [Related]
13. Gender-related differences in prolactinomas. A clinicopathological study.
Schaller B
Neuro Endocrinol Lett; 2005 Apr; 26(2):152-9. PubMed ID: 15855888
[TBL] [Abstract][Full Text] [Related]
14. The expression of AIB1 correlates with cellular proliferation in human prolactinomas.
Carretero J; Blanco EJ; Carretero M; Carretero-Hernández M; García-Barrado MJ; Iglesias-Osma MC; Burks DJ; Font de Mora J
Ann Anat; 2013 May; 195(3):253-9. PubMed ID: 23433587
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis.
Tsuboi K; Shimura T; Masuda N; Ide M; Tsutsumi S; Yamaguchi S; Asao T; Kuwano H
Anticancer Res; 2007; 27(4B):2289-96. PubMed ID: 17695516
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 expression is a potent prognostic marker in colorectal cancer.
Endo K; Kohnoe S; Tsujita E; Watanabe A; Nakashima H; Baba H; Maehara Y
Anticancer Res; 2005; 25(4):3117-21. PubMed ID: 16080575
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 upregulation during tumor progression in head and neck cancer.
Saussez S; Decaestecker C; Mahillon V; Cludts S; Capouillez A; Chevalier D; Vet HK; André S; Toubeau G; Leroy X; Gabius HJ
Laryngoscope; 2008 Sep; 118(9):1583-90. PubMed ID: 18677282
[TBL] [Abstract][Full Text] [Related]
19. [Expression of MMPPs and TIMP and invasiveness in pituitary adenomas].
Wang J; Liu YS
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):647-50. PubMed ID: 16114548
[TBL] [Abstract][Full Text] [Related]
20. [Expression of pituitary tumor transforming gene, endostatin, and basic fibroblast growth factor mRNAs in invasive pituitary adenomas].
Chen L; Liu YS; Wang LS; Yin HG; Hou QT; Liu ZX; Chen LH; Ling F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):651-3, 666. PubMed ID: 16114549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
